Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis.

[1]  J. Collinge,et al.  Decreased Hippocampal Expression of a Glutamate Receptor Gene in Schizophrenia , 1991, British Journal of Psychiatry.

[2]  R. Waziri,et al.  Evidence of glutamatergic deficiency in schizophrenia , 1991, Neuroscience Letters.

[3]  Edythe D. London,et al.  Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophrenia , 1991, Biological Psychiatry.

[4]  J. Garthwaite,et al.  Excitatory amino acid neurotoxicity and neurodegenerative disease. , 1990, Trends in pharmacological sciences.

[5]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[6]  I. Reynolds,et al.  Tricyclic antidepressants block N‐methyl‐D‐aspartate receptors: similarities to the action of zinc , 1988, British journal of pharmacology.

[7]  G. Reynolds,et al.  ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA , 1988, The Lancet.

[8]  J. Garthwaite,et al.  Receptor-linked ionic channels mediate N-methyl-d-aspartate neurotoxicity in rat cerebellar slices , 1987, Neuroscience Letters.

[9]  G. Gibson,et al.  Calcium and the aging nervous system , 1987, Neurobiology of Aging.

[10]  T. Nishikawa,et al.  Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia , 1983, Neuroscience Letters.

[11]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[12]  W. Danielczyk.  [Therapy of akinetic crises]. , 1973, Die Medizinische Welt.

[13]  C. Penders.  [Amantadine in the treatment of Parkinson's disease]. , 1972, Revue medicale de Liege.

[14]  K. Lange,et al.  Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[15]  J. Watkins,et al.  Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. , 1990, Trends in pharmacological sciences.

[16]  J. Kornhuber,et al.  The Dopaminergic and Glutamatergic Systems in Schizophrenia , 1990 .

[17]  F. Benes,et al.  Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. , 1986, Archives of general psychiatry.